

DRAFT



UTAH DEPARTMENT OF HEALTH
STATE MEDICAID PHARMACY AND THERAPEUTICS
COMMITTEE
FRIDAY, March 19, 2009
7:00 a.m. to 8:30 a.m.
Cannon Health Building
ROOM 114



AGENDA

Please note that persons who wish to address the P&T Committee may contact Duane Parke (dparke@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints

1. Review and Approval of Minutes.

2. DUR Board up date
Public comment

3. Co-chair election (pharmacist)

4. Alzheimer, Cholinomimetics Dr. Christinia Beckwith
Public comment
Jung "June" Caranfa, PharmD Novartis

Public comment that responds to the materials presented by the Drug Information Service at the University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the Drug Information Service and are posted in advance on the P&T Committee website

Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:

Drug Information Service
Attn: Christina Beckwith, PharmD
University of Utah Hospitals & Clinics
421 Wakara Way, Suite 204
Salt Lake City, UT 84108

All Division of Health Care Financing data presented at P&T Committee meeting is referenced to gross paid claims from the data-warehouse. Final year-end dollar and unit amounts may be different due to ledger adjustments.

PDL website info at: <http://health.utah.gov/medicaid/pharmacy>
Manufacturer SSDC bid information at: www.rxssdc.org

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Topics for coming P&T Committee meetings

Apr.	Nasal corticosteroids
May.	osteoporosis agents
	Osteoporosis/combos
Jun.	Antiparkinson agents, newer products
	(COMT inhibitors, MAO inhibitors)
	Other dopamine receptor agonists☺

DRAFT

All Division of Health Care Financing data presented at P&T Committee meeting is referenced to gross paid claims from the data-warehouse. Final year-end dollar and unit amounts may be different due to ledger adjustments.

PDL website info at: <http://health.utah.gov/medicaid/pharmacy>
Manufacturer SSDC bid information at: www.rxsdc.org